KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Chemed (CHE) EBITDA (2016 - 2025)

Historic EBITDA for Chemed (CHE) over the last 17 years, with Q3 2025 value amounting to $88.4 million.

  • Chemed's EBITDA fell 1603.93% to $88.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $405.5 million, marking a year-over-year decrease of 266.49%. This contributed to the annual value of $419.4 million for FY2024, which is 715.08% up from last year.
  • As of Q3 2025, Chemed's EBITDA stood at $88.4 million, which was down 1603.93% from $81.8 million recorded in Q2 2025.
  • In the past 5 years, Chemed's EBITDA ranged from a high of $127.1 million in Q4 2024 and a low of $81.8 million during Q2 2025
  • Its 5-year average for EBITDA is $98.6 million, with a median of $99.7 million in 2023.
  • In the last 5 years, Chemed's EBITDA crashed by 2915.52% in 2021 and then skyrocketed by 3317.71% in 2023.
  • Chemed's EBITDA (Quarter) stood at $109.9 million in 2021, then decreased by 14.97% to $93.4 million in 2022, then skyrocketed by 33.18% to $124.4 million in 2023, then grew by 2.19% to $127.1 million in 2024, then tumbled by 30.46% to $88.4 million in 2025.
  • Its EBITDA was $88.4 million in Q3 2025, compared to $81.8 million in Q2 2025 and $108.2 million in Q1 2025.